ME/CFS — myalgic encephalomyelitis and the peptide conversation

ME/CFS — myalgic encephalomyelitis / chronic fatigue syndrome — has spent decades fighting for recognition in mainstream medicine. The historical arc is ugly: patients told it was psychosomatic, told it was depression, told that graded exercise therapy would fix it, told that cognitive behavioral therapy aimed at their "unhelpful illness beliefs" was the appropriate intervention. Graded exercise therapy was the standard of care recommendation in the UK until recently, based on a trial — the PACE trial — that has since been extensively criticized for methodological problems and has had significant portions of its conclusions walked back. In the meantime, patients who followed the recommendation often got worse. The experience of having a serious, incapacitating neurological condition dismissed as a mental health problem by the medical system is one of the defining secondary traumas of this disease.

The Institute of Medicine — now the National Academy of Medicine — issued a report in 2015 that formalized diagnostic criteria and explicitly stated that ME/CFS is a serious, complex, systemic disease. The diagnostic criteria require the following: substantial impairment in the ability to engage in pre-illness levels of activity, lasting at least six months, accompanied by post-exertional malaise, unrefreshing sleep, and either cognitive impairment or orthostatic intolerance. Post-exertional malaise — the hallmark — is defined as the worsening of symptoms following physical or mental exertion that would not have caused a problem before illness onset, and that doesn't resolve with rest the way ordinary fatigue does. The IOM report was important not because it changed the biology, but because it established a framework that obligated medicine to stop treating the condition as a psychiatric curiosity.

What the biology actually is remains an active research question, and multiple mechanisms appear to be operating in different patients and possibly simultaneously in the same patient. Mitochondrial dysfunction is among the most extensively hypothesized: impaired oxidative phosphorylation, reduced ATP production, and abnormal energy metabolism patterns that have been observed in both muscle tissue and immune cells of ME/CFS patients in multiple studies. This lines up with the metabolic crash phenomenology — the way exertion consumes energy reserves that don't replenish normally, producing the lag-time collapse that defines PEM rather than the immediate exhaustion of ordinary overexertion.

Autoimmunity is another serious hypothesis. Researchers including Jonas Bergquist in Sweden have identified autoantibodies against beta-adrenergic and muscarinic receptors in a significant proportion of ME/CFS patients — receptors involved in autonomic nervous system regulation. The implication is that in some patients, the immune system is actively disrupting autonomic function, which would explain the orthostatic intolerance, the heart rate dysregulation, the temperature dysregulation, and the broad systemic character of the illness. Some patients with ME/CFS have shown improvement with rituximab — a B-cell-depleting immunotherapy — in Norwegian trials, though subsequent larger trials didn't replicate this finding uniformly, suggesting significant patient heterogeneity.

Persistent viral activation is a third thread. The illness frequently begins with an infectious trigger — Epstein-Barr virus, enteroviruses, and now SARS-CoV-2 are the most studied. The hypothesis is that in susceptible individuals, something about the viral encounter disrupts normal immune resolution, leaving the immune system in a state of chronic low-level activation that consumes resources and maintains inflammation without clearing an active infection. This would explain the flu-like symptom quality, the immune abnormalities found in research studies, and the overlap with long COVID. It also explains why the illness often follows a relapsing-remitting pattern that tracks loosely with additional immune challenges — other infections, significant stress, overexertion.

Gut microbiome dysregulation has emerged as a meaningful thread over the past decade. Multiple studies have found significant differences in gut microbiome composition between ME/CFS patients and healthy controls, with reductions in key beneficial species and increases in bacteria associated with inflammation. Given the gut's central role in immune regulation, serotonin production, and vagal signaling to the brain, microbiome disruption likely isn't a side feature of ME/CFS — it may be a driver that sustains the underlying dysregulation.

The nervous system dysregulation picture — the autonomic impairment, the central sensitization, the disrupted hypothalamic-pituitary-adrenal axis — connects all of these threads. The body's ability to regulate itself across systems is compromised, and the compromise appears to be both cause and consequence of the energetic and immune dysfunction operating in parallel.

Here is where the peptide conversation enters, with all the appropriate caveats about what the evidence currently supports.

The mitochondrial angle has the most developed mechanistic reasoning. MOTS-c is a peptide encoded in mitochondrial DNA itself — not nuclear DNA — which makes it unusual among peptides in terms of its origin. It functions as a mitochondria-derived signaling molecule that influences metabolic homeostasis, insulin sensitivity, and cellular stress responses. In animal studies, MOTS-c has shown effects on exercise capacity and metabolic efficiency. Human research is early. Its relevance to ME/CFS is hypothesized through the mitochondrial dysfunction pathway, not yet established through clinical trial. SS-31, also known as elamipretide, is a peptide that targets cardiolipin on the inner mitochondrial membrane — the structural lipid that governs the mitochondrion's ability to produce ATP efficiently. SS-31 is in clinical trials for heart failure and Barth syndrome, a mitochondrial disease. Preclinical data in models of mitochondrial dysfunction are encouraging. Human ME/CFS data don't yet exist at clinical trial scale. NAD+ precursors — not peptides strictly, but closely related in the mitochondrial support conversation — have more accessible evidence and more clinical use, including in ME/CFS patients, though controlled trial data are limited. Humanin is another mitochondria-derived peptide with cytoprotective effects in preclinical models; it's earlier in its research trajectory than MOTS-c.

Thymosin Alpha-1 enters the conversation through the immune dysregulation angle. Its mechanism — supporting regulatory T-cell function, modulating innate immunity, and normalizing chronic immune activation — maps onto the immune phenotype observed in ME/CFS patients in research settings. It has a track record in other chronic viral conditions, including HIV and viral hepatitis, where its use is supported by clinical trial data outside the United States. Whether that track record translates to ME/CFS is a hypothesis, not an established fact. Clinicians in integrative and functional medicine settings have used it for patients with ME/CFS on the basis of this mechanism and prior use data. The evidence is preliminary.

Vasoactive intestinal peptide — VIP — has potential relevance through the autonomic and immune regulation pathways. VIP functions as a neuromodulator and has anti-inflammatory effects through multiple mechanisms, including the regulation of mast cells and T-cell populations. In the context of ME/CFS, the hypothesized relevance involves the autonomic dysfunction and the neuroinflammatory component. Dr. Shoemaker's work on VIP in chronic inflammatory response syndrome is the most developed clinical framework, though it was developed for biotoxin illness and is extrapolated rather than directly tested in ME/CFS patients.

BPC-157's role in the ME/CFS conversation is largely through the gut axis. Given the evidence for gut dysbiosis and intestinal permeability in ME/CFS, the hypothesis is that supporting gut mucosal integrity and reducing gut-level inflammation may remove a source of ongoing systemic immune activation. BPC-157 has shown effects on gut healing and anti-inflammatory properties in preclinical models. Human data are limited and mostly not from ME/CFS populations.

What is absolutely foundational — and what no peptide approach replaces — is pacing. Pacing means staying below the threshold that triggers post-exertional malaise, whatever that threshold is for you. It means tracking your heart rate if orthostatic intolerance is a feature (staying below roughly 100 bpm during activity is a common guideline for patients with PEM). It means refusing the cultural narrative that fatigue is a motivational problem. In ME/CFS, it is a physiological one, and every tool in the toolkit only works if the platform of pacing is in place. Sleep optimization, gut health, stress reduction — these aren't adjuncts. They're part of the foundation.

The intersection with long COVID needs naming clearly. The diagnostic overlap between ME/CFS and post-COVID illness is substantial — many long COVID patients meet IOM criteria for ME/CFS, and the physiological similarities are extensive enough that most researchers now consider post-COVID ME/CFS a real diagnostic entity. This is important because it means that the research and clinical infrastructure around ME/CFS is directly relevant to long COVID patients whose illness has persisted, and vice versa: the accelerated research attention long COVID has attracted is generating data that benefits ME/CFS patients who had been waiting decades for the wider medical system to care.

There is no pharmacological cure for ME/CFS. That sentence needs to be stated plainly because the internet wellness ecosystem frequently implies otherwise, and people who are seriously ill can be made to spend significant resources on approaches that won't help. What peptides represent in this context is a set of mechanistically plausible tools for addressing specific physiological dysfunction — mitochondrial, immune, autonomic, gut-based — that a clinician who takes ME/CFS seriously can evaluate in the context of your specific presentation. Not every patient has the same biology. Not every intervention is appropriate for every patient. The evaluation has to come first.

Finding a provider who takes ME/CFS seriously is not a small thing. This is a condition where dismissal has been the default medical response for decades, and where the research infrastructure has been systematically underfunded relative to its disease burden. Post-COVID specialty clinics, ME/CFS-focused academic programs at a growing number of medical centers, and the network of integrative and functional medicine providers with direct experience of the condition are the places to start. The specialist who understands the IOM criteria, who knows what post-exertional malaise actually is, and who can evaluate you as an individual rather than as a diagnostic category is not optional. In ME/CFS, the quality of the clinical relationship is itself part of the treatment.